A major risk factor of type 2 diabetes mellitus (T2DM) is a positive family history of diabetes. First degree relatives (FDR) of patients with T2DM are more insulin resistant and are reported to have ...

—Review the data and clinical implications when comparing early-onset type 2 diabetes in to early-onset type 1 diabetes. Reviewed by Clifton Jackness, MD, Attending Physician in Endocrinology, Lenox ...

Liver stiffness and severe fibrosis, as measured by FibroScan, are independently linked to type 2 diabetes (T2DM) in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), new ...

Researchers in China evaluated 432 patients with HeFH, including 99 with T2DM and 333 without, for prevalence and severity of CAD. Patients in the T2DM group had a greater number of diseased arteries ...

GLP-1RAs were associated with significant reductions in mean blood glucose and weight compared with controls. The use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) appears to be beneficial ...

Prediabetes affects 634.8 million adults globally, i.e., approximately 12% of the adult population (IDF, 2025), with 30.4% ...

Investigators assessed the predictive value of estimated glucose disposal rate on renal outcomes among patients with type 2 diabetes mellitus. Rapid eGFR decline was found to be associated with an ...

Another combination therapy for type 2 diabetes (T2DM) has entered the US market. On August 27, 2015, the FDA approved Synjardy, a combination of the sodium glucose cotransporter 2 (SGLT2) inhibitor, ...

Steps that need to be taken to address unmet needs and optimize outcomes for patients who have chronic kidney disease and type 2 diabetes. Neil B. Minkoff, MD: This question is open to everybody.

Higher proportion of participants achieved HbA1c levels below 6.5% with canagliflozin VS placebo. HealthDay News — Canagliflozin is associated with a clinically meaningful reduction in hemoglobin A1c ...